期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
阿瑞匹坦用于预防女性胃肠道肿瘤患者化疗所致恶心呕吐的疗效研究
1
作者 De-Shen Wang Ming-Tao Hu +12 位作者 Zhi-Qiang Wang Chao Ren Miao-Zhen Qiu Hui-Yan Luo Ying Jin William Pat Fong Shu-Bin Wang Jie-Wen Peng Qing-Feng Zou qiong tan Feng-Hua Wang Yu-Hong Li 梁军(翻译/校对) 《癌症》 CAS 2022年第2期87-96,共10页
背景与目的 预防化疗所致恶心呕吐在肿瘤治疗的全程管理中是十分重要的一环。本研究评价了在高危女性胃肠道肿瘤患者中,在帕洛诺司琼、地塞米松基础上联用阿瑞匹坦能否进一步预防或减轻FOLFIRI方案(氟尿嘧啶、亚叶酸和伊立替康)或FOLFO... 背景与目的 预防化疗所致恶心呕吐在肿瘤治疗的全程管理中是十分重要的一环。本研究评价了在高危女性胃肠道肿瘤患者中,在帕洛诺司琼、地塞米松基础上联用阿瑞匹坦能否进一步预防或减轻FOLFIRI方案(氟尿嘧啶、亚叶酸和伊立替康)或FOLFOX方案(氟尿嘧啶、亚叶酸和奥沙利铂)化疗所致恶心呕吐的发生率和严重程度。方法 本研究为随机、双盲、安慰剂对照、Ⅲ期临床研究。纳入患者为年龄≤50岁的年轻女性,既往饮酒较少或无饮酒史,确诊为胃肠道肿瘤且正在接受FOLFOX或FOLFIRI方案化疗。2015年8月4日至2020年3月31日期间共有248例女性患者入组,按1∶1比率随机分配至干预组和对照组。采用意向性分析评价患者的基线特征和疗效。分析日期为2020年10月30日。患者随机分配至阿瑞匹坦组(阿瑞匹坦:化疗第1天125 mg,化疗开始前60 min口服;第2、3天80 mg,每天早上口服;帕洛诺司琼0.25 mg静脉注射;地塞米松:化疗第1天6 mg,化疗开始前30 min口服)或安慰剂组(安慰剂:化疗第1天125 mg,化疗开始前60 min口服;第2、3天80 mg,每天早上口服;帕洛诺司琼0.25 mg静脉注射;地塞米松:化疗第1天12 mg,化疗开始前30 min口服)。主要研究终点为完全缓解(complete response,CR)率,定义为第1周期化疗后全程(overall phase)无呕吐发作或未使用解救性治疗药物的患者的比例。其他疗效指标,如无恶心、无呕吐的患者比例等,作为次要研究终点和探索性研究终点。结果 共有来自中国4个临床研究中心的248例患者入组,其中243例[阿瑞匹坦组125(51.4%)例、对照组118(48.5%)例]患者可进行疗效和安全性分析。所有患者的平均[mean(SD)]年龄为40.1(7.3)岁。阿瑞匹坦组的CR率显著高于对照组,包括全程[107(87.0%)vs. 80(66.7%),P<0.001]、急性期[114(92.7%)vs. 91(75.8%),P=0.001]和延迟期[109(88.6%)vs. 84 (70.0%),P=0.001]。两组不良事件的发生率[100(80.0%)vs. 96(81.3%),P=0.79]相似,未观察到与阿瑞匹坦治疗相关的3或4级不良事件。多因素分析显示阿瑞匹坦的应用是唯一与全程CR相关的独立因素。结论 在较年轻的、少量饮酒或无饮酒史的胃肠道肿瘤的女性患者中,帕洛诺司琼和地塞米松基础上联用阿瑞匹坦可增强FOLFOX或FOLFIRI方案化疗时的止吐疗效,耐受性良好。 展开更多
关键词 阿瑞匹坦 胃肠道肿瘤 化疗所致恶心呕吐
下载PDF
Fetal Phenotype and Prenatal Diagnosis of Kabuki Syndrome
2
作者 Yan Pan Hong Yao +4 位作者 Gongli Chen qiong tan Qing Chang Yongyi Ma Zhiqing Liang 《Maternal-Fetal Medicine》 CSCD 2023年第3期187-191,共5页
Kabuki syndrome(MIM 147920)is an autosomal dominant rare disease featured with multiple malformations and mental retardation.The main clinical manifestations of Kabuki syndrome are characteristic facial features,skele... Kabuki syndrome(MIM 147920)is an autosomal dominant rare disease featured with multiple malformations and mental retardation.The main clinical manifestations of Kabuki syndrome are characteristic facial features,skeletal abnormalities,dermatoglyphic abnormalities,postpartum growth retardation,mild to moderate mental retardation,as well as other structural and functional abnormalities that may involve multiple systems.The establishment of diagnosis needs to be combined with clinical phenotype and the discovery of pathogenic mutation.Compared with the abundant descriptions and records of genotype-phenotype of postpartum patients,few prenatal diagnosis cases of Kabuki syndrome had been reported,which partially result from lacking the knowledge of its phenotype in fetuses that might suggest the diagnosis.This report performed comprehensive prenatal examinations to identify a fetus's etiology with multiple structural anomalies characterized by ascites,thickening of local skin,and cardiac abnormalities.We ruled out intrauterine infection,thalassemia,and chromosome abnormality by corresponding tests.Finally,trio whole-exome sequencing revealed a de novo heterozygous variation c.15641g>A(p.r5214h)in exon 48 of the KMT2D gene was the fetus's genetic pathogeny causing Kabuki syndrome.This result suggests that Kabuki syndrome should be in the suspected etiology list for prenatal hydrops/ascites.Our study confirmed that prenatal whole-exome sequencing is an efficient tool for diagnosing fetal abnormalities,and a multidisciplinary team is necessary for providing pregnancy guidance to patients. 展开更多
关键词 Prenatal diagnosis Ultrasonography abnormality Kabuki syndrome KMT2D gene Whole exome sequencing
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部